PRESS RELEASE published on 10/02/2026 at 14:30, 1 month 2 days ago Form 8.3 - The Vanguard Group, Inc.: Prologis, Inc. The Vanguard Group, Inc. discloses a 13.50% stake in Prologis, Inc. through Form 8.3. Also making disclosures about SEGRO plc in related dealings Form 8.3 Vanguard Group SEGRO PLC Prologis Inc. 13.50% Stake
PRESS RELEASE published on 10/02/2026 at 14:29, 1 month 2 days ago Form 8.3 - The Vanguard Group, Inc.: RHI Magnesita N.V. The Vanguard Group, Inc. discloses a 2.20% interest in RHI Magnesita N.V. per Form 8.3. Details on disclosed positions and dealings provided Securities Form 8.3 The Vanguard Group Disclosures RHI Magnesita N.V.
BRIEF published on 10/02/2026 at 14:29, 1 month 2 days ago The Vanguard Group Discloses Position in SEGRO plc Form 8.3 Takeover Code Securities Disclosure Vanguard Group SEGRO PLC
BRIEF published on 10/02/2026 at 14:29, 1 month 2 days ago The Vanguard Group Discloses Position in Bodycote plc Form 8.3 Takeover Code Securities Disclosure Vanguard Group Bodycote PLC
PRESS RELEASE published on 10/02/2026 at 14:29, 1 month 2 days ago Form 8.3 - The Vanguard Group, Inc.: Permanent TSB Group Holdings plc The Vanguard Group, Inc. discloses a 1.35% stake in Permanent TSB Group Holdings plc as of 01 October 2026 Irish Takeover Panel Vanguard Group Financial Disclosure Stake Disclosure Permanent TSB
PRESS RELEASE published on 10/02/2026 at 14:27, 1 month 2 days ago Form 8.3 - The Vanguard Group, Inc.: Rotork plc The Vanguard Group, Inc. discloses 5.47% interest in Rotork plc with 44,722,663 securities held. Sale of 3,380 securities at 4.89 GBP per unit Securities Disclosure The Vanguard Group Sale Rotork Plc
PRESS RELEASE published on 10/02/2026 at 14:27, 1 month 2 days ago Form 8.3 - The Vanguard Group, Inc.: Tate & Lyle plc The Vanguard Group, Inc. discloses 4.80% stake in Tate & Lyle plc through Form 8.3 filing as of 01 October 2026 Securities Form 8.3 Disclosure Vanguard Group Tate & Lyle Plc
PRESS RELEASE published on 10/02/2026 at 14:26, 1 month 2 days ago Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc The Vanguard Group, Inc. discloses 3.59% ownership in Spire Healthcare Group plc. Sale of 1,078 1p ordinary securities at 2.48 GBP per unit Securities Vanguard Group Ownership Disclosure Spire Healthcare Sale
PRESS RELEASE published on 10/02/2026 at 14:24, 1 month 2 days ago Form 8.3 - The Vanguard Group, Inc.: SEGRO plc The Vanguard Group, Inc. discloses 5.64% stake in SEGRO plc's ordinary shares as of October 1, 2026, with recent purchase of 4,137 shares at 9.13 GBP each Ordinary Shares The Vanguard Group Share Purchase Stake Disclosure SEGRO PLC
PRESS RELEASE published on 10/02/2026 at 14:24, 1 month 2 days ago Form 8.3 - The Vanguard Group, Inc.: Bodycote plc The Vanguard Group, Inc. discloses a 5.47% interest in Bodycote plc through relevant securities. Dealings include the sale of 704 securities at 9.14 GBP per unit The Vanguard Group Financial Disclosure Securities Dealing Interest Disclosure Bodycote PLC
Published on 11/04/2026 at 23:10, 4 hours 17 minutes ago Ur-Energy Announces Date for Third Quarter 2026 Results and Conference Call and Webcast
Published on 11/04/2026 at 23:00, 4 hours 27 minutes ago Viemed Healthcare Announces Third Quarter 2026 Financial Results
Published on 11/04/2026 at 22:15, 5 hours 12 minutes ago Zomedica Announces Record Third Quarter Revenue of $9.9 Million, Up 22% Year-Over-Year, Net Loss Reduced 48%, with $41 Million in Liquidity
Published on 11/04/2026 at 22:05, 5 hours 22 minutes ago Stabilis Solutions Announces Third Quarter 2026 Results
Published on 11/05/2026 at 03:10, 17 minutes ago SensAI Veritas Launches SensAI Gateway™ and SensAI Helm™: Bringing Risk Intelligence to the Moment of Trust
Published on 11/05/2026 at 00:02, 3 hours 25 minutes ago EQS-Adhoc: NEXTDC Limited: Response to Share Raid by Goodman Group and Digital Realty
Published on 11/04/2026 at 19:41, 7 hours 46 minutes ago EQS-Adhoc: SNP SE Raises Outlook for the Full Year 2026
Published on 11/04/2026 at 19:25, 8 hours 2 minutes ago Menarini Group and Ryvu Therapeutics Announce First Clinical Data from the Phase II JASPIS-01 Study of dapolsertib (MEN1703, SEL24) in Heavily Pretreated Relapsed/Refractory Aggressive B-cell non-Hodgkin Lymphoma at the 2026 ASH Annual Meeting
Published on 11/04/2026 at 18:43, 8 hours 44 minutes ago EQS-Adhoc: Deutsche EuroShop refines its revenue forecast and raises its earnings forecast for the 2026 financial year
Published on 11/04/2026 at 18:00, 9 hours 27 minutes ago The Belgian State and Engie Group have agreed to extend the target date for concluding the Heads of Terms until 12 December 2026
Published on 11/04/2026 at 17:44, 9 hours 43 minutes ago Aéroports de Paris SA - Information regarding the voting rights and shares as of 31 October 2026
Published on 11/04/2026 at 11:56, 15 hours 30 minutes ago Mersen: Number of shares and voting rights as of October 31, 2026
